scispace - formally typeset
M

Matthias Schmid

Researcher at University of Bonn

Publications -  401
Citations -  11820

Matthias Schmid is an academic researcher from University of Bonn. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 43, co-authored 334 publications receiving 7672 citations. Previous affiliations of Matthias Schmid include Newcastle upon Tyne Hospitals NHS Foundation Trust & University of Erlangen-Nuremberg.

Papers
More filters
Journal ArticleDOI

Clinical features and management of human monkeypox: a retrospective observational study in the UK

Hugh Adler, +138 more
TL;DR: The longitudinal clinical course of monkeypox in a high-income setting, coupled with viral dynamics, and any adverse events related to novel antiviral therapies are described, to highlight the urgent need for prospective studies of antivirals for this disease.
Journal ArticleDOI

Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function

Gail Davies, +257 more
TL;DR: In this paper, the authors combine cognitive and genetic data from the CHARGE and COGENT consortia, and UK Biobank (total N = 300,486; age 16-102) and find 148 genome-wide significant independent loci associated with general cognitive function.
Journal ArticleDOI

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Céline Bellenguez, +401 more
- 01 Apr 2022 - 
TL;DR: This paper performed a two-stage genome-wide association study with 111,326 clinically diagnosed/proxy AD cases and 677,663 controls and found 75 risk loci, of which 42 were new at the time of analysis.
Journal ArticleDOI

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

TL;DR: The results suggest that lomustine-temozolomide chemotherapy might improve survival compared with temozolmide standard therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter.